NCT01679197View on ClinicalTrials.gov

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 8, 2012

Primary Completion Date

July 13, 2016

Study Completion Date

July 13, 2016

Conditions
Fatty Liver Disease, NonalcoholicNonalcoholic SteatohepatitisLipodystrophy
Interventions
DRUG

Metreleptin

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Michigan

OTHER

NCT01679197 - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy | Biotech Hunter | Biotech Hunter